- Category
- Small (2024-25)
- Udyam number
- UDYAM-DL-08-0011824

About GLS Pharma Limited
Data last updated:
GLS Pharma Limited is a public limited company based in Hyderabad, Telangana, India, a subsidiary of Aurobindo Pharma Ltd. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 01 September 2004 and has been in existence for over 22 years.
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN U24239TS2004PLC184306. Its GSTIN is 36AACCG2082K1ZK (Telangana). The company holds 8 GST registrations, of which 5 are active.
The company has an authorised share capital of ₹1.3 Cr and a paid-up capital of ₹1.2 Cr. It was formerly known as Gls Pharma Private Limited and Getwell Life Sciences India Private Limited. It is led by directors including Srinivasa Ramachandra Rao Ilapakurthy and Ravikiran Namburi.
Its last annual general meeting (AGM) was held on 22 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Galaxy Floors 22 – 24 Plot No. 1 Survey No. 83/1, Hyderabad Knowledge City Raidurg Panmaktha, Telangana, India – 500032.
As per the financials filed for FY 2023, the company reported a revenue of ₹36.08 Cr, reflecting significant growth compared to the previous year. For the same year it recorded a net profit of ₹1.9 Cr (net margin 5.3%) and EBITDA of ₹5.27 Cr (EBITDA margin 14.6%). Revenue has grown at a compounded annual rate (CAGR) of 11% over three years and 16% over five years.
The company has about 133 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: GLS Pharma. As per MCA filings, the company has open charges of ₹2 Cr and satisfied charges of ₹15.83 Cr on record. Court records list 11 cases involving the company, including 11 filed against it; 2 cases are pending. The company has 7 deals on record (4 funding rounds, 2 secondary share transfers, 1 acquisition), with disclosed funding of ₹88 Lakh; the latest was in August 2022. Its 4 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 smaller; the largest is Filbs Nutra Private Limited with revenue of ₹25.79 Lakh. The company has 12 MSME Form 1 returns on record between 2019 and 2024, listing 238 overdue payments to 81 micro and small suppliers.
GLS Pharma Limited is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-DL-08-0011824). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website glspharma.com.
Company details
Name history
GLS Pharma has undergone 2 name changes throughout its history. The company was previously known as Gls Pharma Private Limited, and Getwell Life Sciences India Private Limited.. The current legal name is Gls Pharma Limited.
| Company Name | Status |
|---|---|
| GLS Pharma Limited | Current |
| Gls Pharma Private Limited | Previous |
| Getwell Life Sciences India Private Limited. | Previous |
CIN history
GLS Pharma has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is U24239TS2004PLC184306, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24239TS2004PLC184306 | Current |
| U24239DL2004PTC128728 | Previous |
| U24239DL2004PLC128728 | Previous |
Recognitions & Rankings of GLS Pharma
Contact details
GLS Pharma Limited's registered office is in Hyderabad, Telangana. Its website is glspharma.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered AddressGalaxy Floors 22 – 24 Plot No. 1 Survey No. 83/1, Hyderabad Knowledge City Raidurg Panmaktha, Telangana, India – 500032
- IndustryPharma, Drug Formulation & Development
To see the full contact details of GLS Pharma Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
GLS Pharma operates one associated brand: GLS Pharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Oncology APIs and anti-cancer products are manufactured. | glspharma.com |
Financials of GLS Pharma Limited
FY 2025 filings availableGLS Pharma Limited reported revenue of ₹36.08 Cr (up 13862% YoY) for FY 2023.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 16% over five years. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | ₹36.08 Cr | ||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹5.27 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹1.9 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 14.6% | ||||
| Net Profit Margin | 5.3% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of GLS Pharma Limited, buy the company report.
Board of directors of GLS Pharma Limited
GLS Pharma has 3 current directors and 19 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Srinivasa Ramachandra Rao Ilapakurthy Also directs: Auro Pharma Limited, Lyfius Pharma Private Limited | Director | 15 Dec 2023 | 2 Years 11 Months | Current |
| Pendem Harish Babu Also directs: Auro Pharma Limited | Additional Director | 25 Oct 2025 | 1 Years 0 Months | Current |
| Ravikiran Namburi | Director | 20 Sep 2024 | 2 Years 1 Months | Current |
Peer comparison
GLS Pharma Limited is compared with the 4 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| GLS Pharma Limitedthis company | ₹36.08 Cr (FY 2023) | ₹1.9 Cr | 5.3% | 13862.0% | 133 | Hyderabad, Telangana, India |
| Filbs Nutra Private Limited | ₹25.79 Lakh (FY 2018) | -14.0% | Udaipur, Rajasthan, India | |||
| Shree Govardhan Pharma Private Limited | ₹25.75 Lakh (FY 2025) | 774.0% | Jaipur, Rajasthan, India | |||
| Austin Lifesciences Private Limited | ₹25.74 Lakh (FY 2022) | -48.0% | Pune, Maharashtra, India | |||
| Kigo Pharma Private Limited | ₹25.72 Lakh (FY 2024) | 7.0% | Telangana, India |
To see the full peer comparison of GLS Pharma Limited, buy the company report.
Auditor
GLS Pharma Limited is audited by G P M & ASSOCIATES for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| G P M & ASSOCIATES | FY 2023 | 015343S |
Shareholding
The shareholding of GLS Pharma Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of GLS Pharma Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 20 Sep 2022 | 100616943 | Canara Bank | ₹2 Cr | Open | |
| 30 Aug 2021 | 100492779 | Canara Bank | ₹2.5 Cr | Satisfied | |
| 15 Dec 2020 | 100411450 | Syndicate Bank | ₹96 Lakh | Satisfied | |
| 14 Dec 2020 | 100411449 | Canara Bank | ₹80 Lakh | Satisfied | |
| 30 Sep 2015 | 10603903 | Syndicate Bank | ₹7.97 Cr | Satisfied |
To see the full charge records of GLS Pharma Limited, buy the company report.
Total charge records: 8 View all charges
Deals & funding
GLS Pharma Limited has 7 deals on record (4 funding rounds, 2 secondary share transfers, 1 acquisition), with disclosed funding of ₹88 Lakh; the latest was in August 2022.
Deals on record (5 of 7)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Aug 2022 | Acquisition | ₹28.05 Cr | Buyer: Aurobindo Pharma Ltd |
| Nov 2017 | Funding round | ₹10 Lakh | Investors: an individual |
| Sep 2016 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: 2 individuals |
| Mar 2012 | Secondary share transfer | Undisclosed | Buyer: 4 individuals Seller: 2 individuals |
| Dec 2011 | Funding round | ₹28 Lakh | Investors: 2 individuals |
To see the full deal history of GLS Pharma Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
GLS Pharma Limited has 11 court cases on record: 11 filed against it. 2 cases are pending and 9 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 6 | 6 | 1 |
| District courts | 4 | 4 | 1 |
| Supreme Court | 1 | 1 | 0 |
Cases on record (5 of 11)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court of Delhi | Court case (RFA(COMM)) | Filed against the company by Biorx Venture Advisors Pvt Ltd. | Pending |
| District court, South, Delhi | Commercial suit | Filed against the company by Biorx Venture Advisors Pvt Ltd | Disposed |
| High Court of Delhi | Court case (CO.PET.) | Filed against the company by Celon Laboratories Limited | Disposed |
| Bombay High Court | Court case (S) | Filed against the company by Aristo Pharmaceuticals Private Limited | Disposed |
| Bombay High Court | Court case (LPETN) | Filed against the company by Aristo Pharmaceuticals Private Limited | Disposed |
To see the full case history of GLS Pharma Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
GLS Pharma Limited has 12 MSME Form 1 returns on record between 2019 and 2024, listing 238 overdue payments to 81 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 81)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Obvez Labs Private Limited | |||
| Levim Biotech LLP | |||
| Avanscure Lifesciences Private Limited | |||
| Bo-Chem Private Limited | |||
| Adley Lab Limited |
To see the full MSME payment records of GLS Pharma Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
GLS Pharma Limited has a workforce of 133 employees on its EPFO records as of May 2026, across 2 active EPFO establishments.
Headcount by financial year
| Financial year | Employees (EPFO) |
|---|---|
| FY 2026-27 | 133 |
| FY 2025-26 | |
| FY 2024-25 | |
| FY 2023-24 | |
| FY 2022-23 | |
| FY 2021-22 | |
| FY 2020-21 | |
| FY 2019-20 | |
| FY 2018-19 | |
| FY 2017-18 | |
| FY 2016-17 |
To see the full employee and EPFO history of GLS Pharma Limited, buy the company report.
GST
GLS Pharma has 8 GST registrations: 5 active and 3 cancelled or inactive. The first 4 active GSTINs are listed below.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 36AACCG2082K1ZK | Telangana | Active | 01 Jul 2017 |
| 07AACCG2082K1ZL | Delhi | Active | 01 Jul 2017 |
| 33AACCG2082K1ZQ | Tamil Nadu | Active | 08 Nov 2017 |
| 18AACCG2082K1ZI | Assam | Active | 08 Feb 2018 |
To see the full GST registrations and return filing status of GLS Pharma Limited, buy the company report.
Recent activity
GLS Pharma Limited has 22 board changes on record since 2010: 3 appointments and 19 cessations. The latest: Pendem Harish Babu was appointed as Additional Director on 25 Oct 2025.
29 earlier events are in the company report.
Frequently asked questions
GLS Pharma is an active public limited company based in Hyderabad, Telangana, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 01 September 2004 (22+ years old) and is registered under CIN U24239TS2004PLC184306.
GLS Pharma has 3 current directors:
- Srinivasa Ramachandra Rao Ilapakurthy - Director
- Pendem Harish Babu - Additional Director
- Ravikiran Namburi - Director
The latest financial statements of GLS Pharma on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 22 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of GLS Pharma is 36AACCG2082K1ZK, registered in Telangana. The company has 8 GST registrations in all, of which 5 are active and 3 are cancelled or inactive. Other active GSTINs include 07AACCG2082K1ZL (Delhi), 33AACCG2082K1ZQ (Tamil Nadu), 18AACCG2082K1ZI (Assam).
The CIN (Corporate Identification Number) of GLS Pharma is U24239TS2004PLC184306. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
GLS Pharma has 11 court cases on record: 11 filed against it. 2 are pending. Most are in the high courts.
GLS Pharma was incorporated on 01 September 2004, making it 22+ years old. It is registered with the Registrar of Companies, Hyderabad.
GLS Pharma has 7 deals on record (4 funding rounds, 2 secondary share transfers, 1 acquisition), with disclosed funding of ₹88 Lakh; the latest was in August 2022.
The peers of GLS Pharma by revenue are Filbs Nutra Private Limited, Shree Govardhan Pharma Private Limited, Austin Lifesciences Private Limited, Kigo Pharma Private Limited, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Pendem Harish Babu was appointed as Additional Director on 25 Oct 2025. Ravikiran Namburi ceased to be Additional Director on 21 Sep 2025. Godi Bhaskara Reddy ceased to be Additional Director on 19 Aug 2025. GLS Pharma has 22 board changes on record in total.
Yes, GLS Pharma is registered as a small enterprise under Udyam registration (number: UDYAM-DL-08-0011824).
GLS Pharma has 12 MSME Form 1 returns on record between 2019 and 2024, listing 238 overdue payments to 81 micro and small suppliers. The latest return was filed on 30 Apr 2024.

